Compare Inovio Pharmaceuticals Inc (INO) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Impinj Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Impinj Inc trades at $186 (market cap $5.60B). The key difference: Impinj Inc is far larger — about 49.9× Inovio Pharmaceuticals Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Impinj Inc for 22 Days on average.
| INO | PI | |
|---|---|---|
Market Cap | $112.19M | $5.60B |
Volume | 3,201,278 | 9,929 |
Sector | Health | Technology |
52-Week High | $2.65 | $241.91 |
52-Week Low | $0.66 | $91.34 |
Typical Hold Time | 43 Days | 22 Days |
Enterprise Value | $83.51M | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Impinj (PI) trades at $191.04, up 3.81% with strong technical momentum and bullish moving average signals. The company shows revenue growth with Q2 2026 earnings beating estimates, though profitability remains challenged with negative net margins. Analyst consensus is strongly bullish with 16 buy ratings and a $178.83 price target, while recent news highlights the company's positioning in RFID technology and upcoming Q3 earnings.
The stock presents growth potential from expanding RFID adoption but faces risks from persistent unprofitability and high valuation multiples. Current technical strength and institutional interest support near-term upside, though investors should monitor Q3 earnings results and margin improvement for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
